The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > ORGANIZATION
ORGANIZATION
- Raise Copay Rates to 20% for Seniors Over 75 ASAP: 5 Insurers
November 5, 2020
- Sales Reps in Japan Decrease to 57,158 in FY2019, Down for 6 Years Running: Survey
November 5, 2020
- PhRMA Makes 3-Pronged Proposal to Japan Govt, Calls for Fueling Innovation, Investment, and Digitalization
October 29, 2020
- Japan Trade Groups Step Up Lobbying Campaigns as Diet Convenes, Renew Call for “Cautious Approach” to Off-Year Re-Pricing
October 27, 2020
- FPMAJ Urges Drug Makers to Ensure Stable Supply of Newly Listed Products
October 16, 2020
- COVID-19 Affecting Reimbursement Fee Incentive for Biosimilars: JPA Exec
October 16, 2020
- Take COVID as Opportunity to “Reset” Overdependence on Drug Price Cuts: PhRMA Chief
October 12, 2020
- Don’t Politicize Coronavirus Vaccine Introduction: Drug Damage Watchdog
October 8, 2020
- Ex-MHLW Official Takeyuki Sato Named JGA Director General
October 2, 2020
- Coronavirus Vaccines Must Be Offered to All Humanity: EFPIA Japan Webinar
October 1, 2020
- Generic Use Rate at 79.3% in April-June, Just Shy of Govt Target: JGA
October 1, 2020
- EFPIA Global, Japan Chiefs Call for Appropriate Reward for Innovation
September 30, 2020
- New Cabinet Well Organized, Full of People with Practical Experience: JPMA Director General
September 23, 2020
- Drug Wholesalers’ Sales Up 2.54%, Improving Profit Rates in FY2019: JPWA
September 23, 2020
- Ex-MHLW Councilor Mori to Become JPMA’s Sr. Managing Director in October
September 18, 2020
- Japan Pharma Groups Stepping Up Lobbying on FY2021 Budget, Tax Reform
September 17, 2020
- JPMA Policy Proposal Calls for Govt’s Flexibility towards Coronavirus Vaccinations, Steps to Expedite Visas for Foreign Technicians
September 15, 2020
- EFPIA Japan Issues Statement on Vaccination System under COVID-19 Crisis, Calls for Eliminating Obstacles for Vaccine Imports
September 14, 2020
- JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
September 7, 2020
- Generic APIs at Crossroads - 2: Traders’ Group Urges Simpler Regulatory Procedures to Facilitate API Substitution
August 13, 2020
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…